Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Gains from Sales and Divestitures: 2022

  • Fennec Pharmaceuticals' Gains from Sales and Divestitures was N/A to $26,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $26,000, marking a year-over-year change of. This contributed to the annual value of $26,000 for FY2022, which is N/A change from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Gains from Sales and Divestitures of $26,000 as of Q4 2022.
  • Fennec Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $26,000 during Q4 2022, with a 5-year trough of $26,000 in Q4 2022.
  • Moreover, its 1-year median value for Gains from Sales and Divestitures was $26,000 (2022), whereas its average is $26,000.